Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5065-5076

  Medinger, Michael ^a   Esser, Norbert ^b   Zirrgiebel, Ute ^b   Ryan, Anderson ^c   Jürgensmeier, Juliane M ^c   Drevs, Joachim ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PROQINASE GMBH   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Biomarkers; Cediranib; Murine renal cell carcinoma; VEGF

Indexed keywords

CEDIRANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75149149393     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Medinger M and Drevs J: Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 11: 1139-1149, 2005.
3. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
4. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
5. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
6. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N and Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230, 2001.
7. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C and Alitalo K: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660, 2008.
8. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C and Marme D: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819-4824, 2000.
9. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G and Totzke F: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000.
10. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
11. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J and Smith MA: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 581-587, 2008.
12. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM and Ogilvie DJ: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400, 2005.
13. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL and Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124,2007.
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134,2007.
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
17. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, Wedge SR, Jurgensmeier JM and Alitalo K: The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68: 4754-4762, 2008.
18. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jurgensmeier JM, Wedge SR and Barry ST: Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6: 2198-2208, 2007.
19. Drevs J, Siegelt P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O and Unger C: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054, 2007.
20. van Cruijsen H, Voest EE, van Herpen CML, Hoekman K, Witteveen PO, Tjin-A-Ton ML, Punt CJ, Puchalski T, Milenkova T and Giaccone G: Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 24(S18): abst 3017, 2006.
21. Shields AF, Heath E, DeLuca P, Pilat M, Wozniak A, Gadgeel S, Puchalski T, Xu J, Liu Q and LoRusso P: AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study. J Clin Oncol 25(18S): abst 3544, 2007.
22. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C and Small EJ: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25: 445-451, 2007.
23. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY and Jain RK: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95, 2007.
24. Mulders P, Hawkins R, Nathan P, de Jong I, Mookerjee B, Osanto S, Pike L, Porfiri E, Protheroe A and Gore ME: Cediranib (Recentin™) in patients with advanced renal cell carcinoma: results of a randomized phase II study. 7th International Kidney Cancer Symposium 2008; abst 21.
25. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O and Khayat D: Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 20: 1446-1448, 2002.
26. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M and Marmé D: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16: 558-565, 2005.
27. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N and Marme D: Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7: 1992-1997, 2001.
28. Wittig BM, Kaulen H, Thees R, Schmitt C, Knolle P, Stock J, Meyer zum Buschenfelde KH and Dippold W: Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 32A: 1215-1218, 1996.
29. Klisch J, Kubalek R, Scheufler KM, Zirrgiebel U, Drevs J and Schumacher M: Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study. Neuroradiology 47: 10-17, 2005.
30. Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ and Esser N: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347-354, 2004.
31. Herbst RS, Heymach JV, O'Reilly MS, Onn A and Ryan AJ: Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16: 239-249, 2007.
32. Murphy GP and Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1025, 1973.
33. Nishimatsu H, Takeuchi T, Ueki T, Kajiwara T, Moriyama N, Ishida T, Li B, Kakizoe T and Kitamura T: CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol Immunother 48: 56-61, 1999.
34. Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N and Kawabe K: Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 43: 375-381, 1997.
35. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
36. Bates DO, Heald RI, Curry FE and Williams B: Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol 533: 263-272, 2001.
37. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004.
38. Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA and Myers JN: The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 13: 4519-4527, 2007.
39. Kut C, Mac GF and Popel AS: Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97: 978-985, 2007.
40. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD and Demetri GD: Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10: 5732-5740, 2004.
41. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J and McSheehy PM: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 57: 761-771, 2006.
42. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD and Heymach JV: Blood-based biomarkers of SU1 1248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13: 2643-2650, 2007.
43. Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ and Kerbel RS: Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64: 6616-6625, 2004.
44. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ and Kerbel RS: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104: 17069-17074, 2007.
45. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van SP, Francia G, Xu P, Mutsaers AJ, Dumont DJ and Kerbel RS: Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529, 2008.
46. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X and Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2: 315-326, 2004.
47. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N and Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393, 2008.
48. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ and Rini BI: Activity of SU1 1248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006.